Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pustular and crusted lesions in systemic lupus erythematosus: A case report.
J Family Med Prim Care
November 2024
Department of Dermatology, Venereology and Leprosy, SRM Medical College and Research Centre, Chengalpattu, Tamil Nadu, India.
Systemic lupus erythematosus (SLE) is the prototype of an autoimmune disease with various manifestations in the skin and several other organs. Subacute cutaneous lupus erythematosus may present with annular and psoriasiform lesions. There have been case reports of pustular lesions in SLE.
View Article and Find Full Text PDFAcute generalised exanthematous pustulosis (AGEP) is a rare drug-induced pustular eruption characterised by the rapid onset of superficial pinhead pustules. We discuss the case of a 27-year-old man who presented with a generalised pustular eruption on the neck, trunk and limbs. He commenced upadacitinib for the treatment of atopic dermatitis (AD) 6 months before developing the rash, and the dose was increased from 15 to 30 mg daily, 3 months prior.
View Article and Find Full Text PDFComplete skin remission of Sneddon-Wilkinson disease with acalabrutinib.
Australas J Dermatol
November 2024
Sir Peter McCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Sneddon-Wilkinson (SW) disease is rare condition which typically occurs in the context of a monoclonal immunoglobulin and treatment options have not been well studied. Here we present a case of a 65-year-old female with SW with underlying, otherwise indolent, lymphoplasmacytic lymphoma (LPL) with an IgA paraprotein, who achieved a complete skin remission with the administration of the Bruton Tyrosine Kinase inhibitor (BTKi), acalabrutinib.
View Article and Find Full Text PDFAcute generalized exanthematous pustulosis induced by icotinib: a case report and literature review.
Front Pharmacol
August 2024
Department of Dermatology, General Hospital of Northern Theater Command, Shenyang, China.
Acute generalized exanthematous pustulosis, an infrequent adverse drug reaction, mainly results from drugs. Clinically, acute generalized exanthematous pustulosis manifests as a high fever, with skin lesions of small monomorphic subcorneal sterile pustules on an erythematous that presents at 1-4 days after medication exposure. The incidence of acute generalized exanthematous pustulosis varies from 3/1, 000, 000 to 5/1, 000, 000, while the mortality rate is typically around 5%.
View Article and Find Full Text PDFClinical characteristics, treatment and outcome of clindamycin induced acute generalized exanthematous pustulosis.
Arch Dermatol Res
August 2024
College of Pharmacy, Changsha Medical University, Changsha, 410219, Hunan, China.
Article Synopsis
- Acute generalized exanthematous pustulosis (AGEP) is a serious but rare reaction to clindamycin, characterized by pustular lesions, fever, and itching, primarily seen in females around the median age of 57.
- In a study of 35 patients, AGEP typically appeared 2 days after starting clindamycin, with lesions mostly affecting the extremities and trunk, along with significant neutrophil elevation.
- The condition is self-limiting, and patients experienced recovery after stopping the drug and receiving supportive care, with a typical recovery time of 9 days; thus, awareness and prompt action by clinicians are crucial.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!